.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The FLAURA trial compared first-line osimertinib with older EGFR tyrosine kinase inhibitors in patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Osimertinib significantly prolonged progression-free survival and later demonstrated an overall-survival advantage, establishing it as a major example of biomarker-directed therapy in thoracic oncology. The study reinforces a core principle for clinicians: modern lung-cancer care increasingly depends on obtaining adequate tissue or other validated material for molecular testing before treatment selection. For HCPs, this means that diagnosis, staging, tissue acquisition, pathology, and molecular testing should be planned as a single workflow. The conference’s emphasis on biomarkers, EBUS-TBNA staging, and access beyond metro centres is directly relevant because a treatment strategy is only as effective as the diagnostic pathway that identifies the patient who should receive it. The broader lesson is that procedural pulmonology and precision oncology are now tightly linked. Efficient, high-quality tissue acquisition can determine whether a patient receives a targeted therapy with proven survival benefit rather than an empiric treatment chosen without genomic information.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The FLAURA trial compared first-line osimertinib with older EGFR tyrosine kinase inhibitors in patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Osimertinib significantly prolonged progression-free survival and later demonstrated an overall-survival advantage, establishing it as a major example of biomarker-directed therapy in thoracic oncology. The study reinforces a core principle for clinicians: modern lung-cancer care increasingly depends on obtaining adequate tissue or other validated material for molecular testing before treatment selection. For HCPs, this means that diagnosis, staging, tissue acquisition, pathology, and molecular testing should be planned as a single workflow. The conference’s emphasis on biomarkers, EBUS-TBNA staging, and access beyond metro centres is directly relevant because a treatment strategy is only as effective as the diagnostic pathway that identifies the patient who should receive it. The broader lesson is that procedural pulmonology and precision oncology are now tightly linked. Efficient, high-quality tissue acquisition can determine whether a patient receives a targeted therapy with proven survival benefit rather than an empiric treatment chosen without genomic information.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
